Published in Trends Pharmacol Sci on March 09, 2009
Mechanisms underlying inflammation in neurodegeneration. Cell (2010) 7.66
Dual roles for perivascular macrophages in immune-to-brain signaling. Neuron (2010) 2.24
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: Implications for a role of COX-1. Brain Behav Immun (2009) 1.76
Cyclooxygenase-1 is involved in the inhibition of hippocampal neurogenesis after lipopolysaccharide-induced neuroinflammation. Cell Cycle (2011) 1.54
Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J Neurosci (2011) 1.37
Effects of neuroinflammation on the regenerative capacity of brain stem cells. J Neurochem (2011) 1.27
Cyclooxygenase-1-dependent prostaglandins mediate susceptibility to systemic inflammation-induced acute cognitive dysfunction. J Neurosci (2013) 1.13
Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol Brain (2010) 1.13
Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications. Biochimie (2010) 1.13
Sleep and innate immunity. Front Biosci (Schol Ed) (2011) 1.11
Expression and cellular localization of cyclooxygenases and prostaglandin E synthases in the hemorrhagic brain. J Neuroinflammation (2011) 1.10
Cerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamic-pituitary-adrenal axis activation by inflammatory stimuli. J Neurosci (2009) 1.10
Stress responses: the contribution of prostaglandin E(2) and its receptors. Nat Rev Endocrinol (2010) 1.07
Induction of COX-2 enzyme and down-regulation of COX-1 expression by lipopolysaccharide (LPS) control prostaglandin E2 production in astrocytes. J Biol Chem (2012) 1.00
Cyclooxygenases-1 and -2 differentially modulate leukocyte recruitment into the inflamed brain. Pharmacogenomics J (2009) 0.98
Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation. Front Cell Neurosci (2015) 0.97
Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium? J Neuroimmune Pharmacol (2011) 0.94
The effect of progesterone dose on gene expression after traumatic brain injury. J Neurotrauma (2011) 0.94
Cyclooxygenase-1 mediates prostaglandin E(2) elevation and contextual memory impairment in a model of sustained hippocampal interleukin-1beta expression. J Neurochem (2010) 0.93
Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem (2012) 0.91
NSAIDs acutely inhibit TRPC channels in freshly isolated rat glomeruli. Biochem Biophys Res Commun (2011) 0.90
Kaempferol acts through mitogen-activated protein kinases and protein kinase B/AKT to elicit protection in a model of neuroinflammation in BV2 microglial cells. Br J Pharmacol (2011) 0.90
Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition. Proc Natl Acad Sci U S A (2015) 0.90
Redox control of microglial function: molecular mechanisms and functional significance. Antioxid Redox Signal (2014) 0.90
Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration. Curr Neuropharmacol (2010) 0.88
Developmental onset of bilirubin-induced neurotoxicity involves Toll-like receptor 2-dependent signaling in humanized UDP-glucuronosyltransferase1 mice. J Biol Chem (2014) 0.88
Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial. BMJ Open (2012) 0.86
Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide. J Neuroinflammation (2013) 0.85
Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration. Front Mol Neurosci (2015) 0.84
Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.84
Integrated proteomics identified novel activation of dynein IC2-GR-COX-1 signaling in neurofibromatosis type I (NF1) disease model cells. Mol Cell Proteomics (2013) 0.83
The effect of nicotinamide on gene expression in a traumatic brain injury model. Front Neurosci (2013) 0.83
The role of nitric oxide in prostaglandin biology; update. Nitric Oxide (2011) 0.83
Blue Light Modulates Murine Microglial Gene Expression in the Absence of Optogenetic Protein Expression. Sci Rep (2016) 0.82
Celecoxib attenuates systemic lipopolysaccharide-induced brain inflammation and white matter injury in the neonatal rats. Neuroscience (2013) 0.82
Coordinated gene expression of neuroinflammatory and cell signaling markers in dorsolateral prefrontal cortex during human brain development and aging. PLoS One (2014) 0.81
Prostaglandin E2 synthases in neurologic homeostasis and disease. Prostaglandins Other Lipid Mediat (2009) 0.80
Lentiviral infection of rhesus macaques causes long-term injury to cortical and hippocampal projections of prostaglandin-expressing cholinergic basal forebrain neurons. J Neuropathol Exp Neurol (2012) 0.80
A novel role of the STAT3 pathway in brain inflammation-induced human neural progenitor cell differentiation. Curr Mol Med (2013) 0.79
Staging anti-inflammatory therapy in Alzheimer's disease. Front Aging Neurosci (2010) 0.79
Rutin, a Flavonoid That Is a Main Component of Saussurea involucrata, Attenuates the Senescence Effect in D-Galactose Aging Mouse Model. Evid Based Complement Alternat Med (2012) 0.79
Peripherally triggered and GSK-3β-driven brain inflammation differentially skew adult hippocampal neurogenesis, behavioral pattern separation and microglial activation in response to ibuprofen. Transl Psychiatry (2014) 0.79
Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors. ACS Med Chem Lett (2014) 0.78
Neuroinflammation in overnutrition-induced diseases. Vitam Horm (2013) 0.78
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA? Philos Trans R Soc Lond B Biol Sci (2015) 0.78
Acacetin inhibits glutamate release and prevents kainic acid-induced neurotoxicity in rats. PLoS One (2014) 0.78
Cyclooxygenase expression and prostaglandin levels in central nervous system tissues during the course of chronic relapsing experimental autoimmune encephalomyelitis (EAE). Inflamm Res (2011) 0.78
A role for cyclooxygenase-1 in beta-amyloid-induced neuroinflammation. Aging (Albany NY) (2009) 0.78
COX1 and COX2 expression in non-neuronal cellular compartments of the rhesus macaque brain during lentiviral infection. Neurobiol Dis (2011) 0.78
Imaging Neuroinflammation - from Bench to Bedside. J Clin Cell Immunol (2014) 0.77
Interactions between prostaglandins, leukotrienes and HIV-1: possible implications for the central nervous system. Retrovirology (2012) 0.77
Modulation of dendritic cell function by PGE2 and DHA: a framework for understanding the role of dendritic cells in neuroinflammation. Clin Lipidol (2011) 0.77
PET radiotracer [¹⁸F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation. Eur J Med Chem (2014) 0.77
Neuronal overexpression of cyclooxygenase-2 does not alter the neuroinflammatory response during brain innate immune activation. Neurosci Lett (2010) 0.77
Higher pain scores, similar opioid doses and side effects associated with antipyretic analgesics in specialised tertiary pain care. Inflamm Res (2010) 0.76
Pain Mechanisms and Centralized Pain in Temporomandibular Disorders. J Dent Res (2016) 0.76
Non-Steroidal Anti-Inflammatory Drugs and Brain Inflammation: Effects on Microglial Functions. Pharmaceuticals (Basel) (2010) 0.76
Lack of enantiomeric influence on the brain cytoprotective effect of ibuprofen and flurbiprofen. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.76
Using anesthetics and analgesics in experimental traumatic brain injury. Lab Anim (NY) (2013) 0.76
Deleting IGF-1 receptor from forebrain neurons confers neuroprotection during stroke and upregulates endocrine somatotropin. J Cereb Blood Flow Metab (2016) 0.76
Concurrent Treatment with Taxifolin and Cilostazol on the Lowering of β-Amyloid Accumulation and Neurotoxicity via the Suppression of P-JAK2/P-STAT3/NF-κB/BACE1 Signaling Pathways. PLoS One (2016) 0.75
Cyclooxygenase Isoform Exchange Blocks Brain-Mediated Inflammatory Symptoms. PLoS One (2016) 0.75
Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration. Ann N Y Acad Sci (2016) 0.75
Anticonvulsive Effects of Licofelone on Status Epilepticus Induced by Lithium-pilocarpine in Wistar Rats: a Role for Inducible Nitric Oxide Synthase. J Epilepsy Res (2016) 0.75
n-Hexane Insoluble Fraction of Plantago lanceolata Exerts Anti-Inflammatory Activity in Mice by Inhibiting Cyclooxygenase-2 and Reducing Chemokines Levels. Sci Pharm (2017) 0.75
Functional magnetic resonance imaging in chronic ischaemic stroke. Philos Trans R Soc Lond B Biol Sci (2016) 0.75
Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation. Pharmaceuticals (Basel) (2010) 0.75
Cyclooxygenase-1 as a Potential Therapeutic Target for Seizure Suppression: Evidences from Zebrafish Pentylenetetrazole-Seizure Model. Front Neurol (2016) 0.75
Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide. J Neuroinflammation (2017) 0.75
Highly Selective Cyclooxygenase-1 Inhibitors P6 and Mofezolac Counteract Inflammatory State both In Vitro and In Vivo Models of Neuroinflammation. Front Neurol (2017) 0.75
Evidence for inflammation-mediated memory dysfunction in gastropods: putative PLA2 and COX inhibitors abolish long-term memory failure induced by systemic immune challenges. BMC Neurosci (2013) 0.75
Nepeta Dschuparensis Bornm Extract Moderates COX-2 and IL-1β Proteins in a Rat Model of Cerebral Ischemia. Iran J Med Sci (2017) 0.75
Disruption of neurogenesis by hypothalamic inflammation in obesity or aging. Rev Endocr Metab Disord (2013) 0.75
Abnormal COX2 protein expression may be correlated with poor prognosis in oral cancer: a meta-analysis. Biomed Res Int (2014) 0.75
A role for lipids as agents to alleviate stroke damage: the neuroprotective effect of 2-hydroxy arachidonic acid. Neural Regen Res (2017) 0.75
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science (2005) 14.43
Microglia: a sensor for pathological events in the CNS. Trends Neurosci (1996) 12.00
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci (2007) 11.24
Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci (2007) 11.11
Prostaglandin E receptors. J Biol Chem (2007) 5.29
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology (2005) 3.78
Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol (2006) 3.39
Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med (2006) 2.94
Inflammatory processes in Alzheimer's disease. J Neuroimmunol (2007) 2.91
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A (2003) 2.74
Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol (2007) 2.67
Clinical trial of indomethacin in Alzheimer's disease. Neurology (1993) 2.58
NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging (2006) 2.55
Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol (2008) 2.46
Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol (2004) 2.45
Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices. Glia (2001) 2.39
Protective effects of NSAIDs on the development of Alzheimer disease. Neurology (2008) 2.21
Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A (2001) 2.16
Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem (2002) 2.11
Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev (2006) 1.96
Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J (2007) 1.93
Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology (2004) 1.92
Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J Neurosci (2000) 1.76
Modulation of inflammation in brain: a matter of fat. J Neurochem (2007) 1.74
Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res (2004) 1.60
Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology (2007) 1.52
Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol (2004) 1.47
Nuclear factor-kappaB activation and postischemic inflammation are suppressed in CD36-null mice after middle cerebral artery occlusion. J Neurosci (2008) 1.46
No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology (2008) 1.45
Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia (2005) 1.42
Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann Neurol (1994) 1.34
Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol (2007) 1.34
Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J Neurochem (2003) 1.33
Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation (2006) 1.32
Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation (2008) 1.30
Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol (2007) 1.29
Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology (2005) 1.28
The brain as a target for inflammatory processes and neuroprotective strategies. Ann N Y Acad Sci (2007) 1.27
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord (2006) 1.27
Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des (2008) 1.26
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology (2006) 1.21
Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice. J Cereb Blood Flow Metab (2004) 1.20
Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem (2004) 1.17
Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation (2007) 1.17
Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models. J Neurochem (2007) 1.16
Cyclo-oxygenase-1 and -2 differently contribute to prostaglandin E2 synthesis and lipid peroxidation after in vivo activation of N-methyl-D-aspartate receptors in rat hippocampus. J Neurochem (2005) 1.15
Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.15
Prolonged cyclooxygenase-2 induction in neurons and glia following traumatic brain injury in the rat. J Neurotrauma (2000) 1.12
Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol (1999) 1.12
Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem (2002) 1.08
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J Med Chem (2005) 1.07
Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J Clin Neurosci (2008) 1.03
Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli. J Neurochem (2005) 1.03
Effect of endotoxin on permeability of bovine cerebral endothelial cell layers in vitro. J Pharmacol Exp Ther (1996) 1.03
Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury. J Neurosurg (2002) 1.01
Gene expression of cyclooxygenase-1 and Ca(2+)-independent phospholipase A(2) is altered in rat hippocampus during normal aging. Brain Res Bull (2007) 1.00
Inhibition of cyclooxygenase 2 by nimesulide improves cognitive outcome more than motor outcome following diffuse traumatic brain injury in rats. Exp Brain Res (2002) 1.00
Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain (2006) 1.00
Cyclooxygenase-1 and -2 enzymes differentially regulate the brain upstream NF-kappa B pathway and downstream enzymes involved in prostaglandin biosynthesis. J Neurochem (2006) 0.99
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology (2007) 0.98
Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury. J Neurotrauma (2000) 0.97
Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur J Neurosci (2003) 0.95
Endotoxin-induced uveitis in cyclooxygenase-2-deficient mice. Invest Ophthalmol Vis Sci (2004) 0.92
Cyclooxygenase-2, prostaglandin E2, and microglial activation in prion diseases. Int Rev Neurobiol (2007) 0.92
Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice. Brain Res Bull (2007) 0.90
Cyclooxygenase-2, prostaglandin synthases, and prostaglandin H2 metabolism in traumatic brain injury in the rat. J Neurotrauma (2002) 0.88
Genetic disruption of cyclooxygenase-2 does not improve histological or behavioral outcome after traumatic brain injury in mice. J Neurosci Res (2008) 0.87
Selective accumulation of cyclooxygenase-1-expressing microglial cells/macrophages in lesions of human focal cerebral ischemia. Acta Neuropathol (2000) 0.86
Cyclooxygenase-1 and -2 in brains of patients who died with sporadic Creutzfeldt-Jakob disease. J Mol Neurosci (2003) 0.84
Selective increase of neuronal cyclooxygenase-2 (COX-2) expression in vulnerable brain regions of rats with experimental Wernicke's encephalopathy: effect of nimesulide. Metab Brain Dis (2008) 0.83
Limited role of COX-2 in HIV Tat-induced alterations of tight junction protein expression and disruption of the blood-brain barrier. Brain Res (2007) 0.83
Endocannabinoids and the brain immune system: new neurones at the horizon? J Neuroendocrinol (2008) 0.82
Is prostaglandin E(2) a pathogenic factor in amyotrophic lateral sclerosis? Ann Neurol (2006) 0.80
Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis. J Intern Med (2008) 0.79
Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J (2007) 1.93
Unesterified docosahexaenoic acid is protective in neuroinflammation. J Neurochem (2013) 1.68
The contribution of myelin to magnetic susceptibility-weighted contrasts in high-field MRI of the brain. Neuroimage (2011) 1.68
Cyclooxygenase-1 is involved in the inhibition of hippocampal neurogenesis after lipopolysaccharide-induced neuroinflammation. Cell Cycle (2011) 1.54
Is it time to standardize ethics guiding the peer review process? Lipids (2007) 1.40
Rat brain arachidonic acid metabolism is increased by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide. J Neurochem (2004) 1.33
Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation (2008) 1.30
Effects of neuroinflammation on the regenerative capacity of brain stem cells. J Neurochem (2011) 1.27
Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry (2002) 1.24
Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. J Neurochem (2011) 1.22
Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY) (2009) 1.13
Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications. Biochimie (2010) 1.13
Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation (2012) 1.13
Modulatory role of cyclooxygenase-2 in cerebrovascular coupling. Neuroimage (2006) 1.03
Gene expression of cyclooxygenase-1 and Ca(2+)-independent phospholipase A(2) is altered in rat hippocampus during normal aging. Brain Res Bull (2007) 1.00
Cyclooxygenase-1 and -2 enzymes differentially regulate the brain upstream NF-kappa B pathway and downstream enzymes involved in prostaglandin biosynthesis. J Neurochem (2006) 0.99
Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol Psychiatry (2004) 0.98
Cyclooxygenase-1 and -2 differentially modulate lipopolysaccharide-induced blood-brain barrier disruption through matrix metalloproteinase activity. J Cereb Blood Flow Metab (2009) 0.96
Plasma free polyunsaturated fatty acid levels are associated with symptom severity in acute mania. Bipolar Disord (2007) 0.96
Differential gene expression patterns in cyclooxygenase-1 and cyclooxygenase-2 deficient mouse brain. Genome Biol (2007) 0.96
Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. Exp Neurol (2003) 0.94
Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem (2012) 0.91
Quenching of intracellular ROS generation as a mechanism for oleate-induced reduction of endothelial activation and early atherogenesis. Thromb Haemost (2002) 0.91
Decrease in the AP-2 DNA-binding activity and in the protein expression of AP-2 alpha and AP-2 beta in frontal cortex of rats treated with lithium for 6 weeks. Neuropsychopharmacology (2005) 0.90
Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice. Brain Res Bull (2007) 0.90
Co-localization of cytosolic phospholipase A2 and cyclooxygenase-2 in Rhesus monkey cerebellum. Brain Res Mol Brain Res (2003) 0.90
The cyclooxygenase-2 pathway via the PGE₂ EP2 receptor contributes to oligodendrocytes apoptosis in cuprizone-induced demyelination. J Neurochem (2011) 0.86
NMDA-induced seizure intensity is enhanced in COX-2 deficient mice. Neurotoxicology (2008) 0.85
Regional protein levels of cytosolic phospholipase A2 and cyclooxygenase-2 in Rhesus monkey brain as a function of age. Brain Res Bull (2006) 0.83
Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2010) 0.82
Ginkgo biloba extracts EGb 761 and bilobalide increase NADH dehydrogenase mRNA level and mitochondrial respiratory control ratio in PC12 cells. Neurochem Res (2002) 0.82
Topiramate does not alter the kinetics of arachidonic or docosahexaenoic acid in brain phospholipids of the unanesthetized rat. Neurochem Res (2005) 0.82
3,6'-Dithiothalidomide, a new TNF-α synthesis inhibitor, attenuates the effect of Aβ1-42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit. J Neurochem (2012) 0.82
The effect of chronic lithium on arachidonic acid release and metabolism in rat brain does not involve secretory phospholipase A2 or lipoxygenase/cytochrome P450 pathways. Brain Res Bull (2004) 0.82
Alterations of brain eicosanoid synthetic pathway in multiple sclerosis and in animal models of demyelination: role of cyclooxygenase-2. Prostaglandins Leukot Essent Fatty Acids (2013) 0.80
Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism. Psychopharmacology (Berl) (2005) 0.80
Rethinking the role of cyclooxygenase-1 in neuroinflammation: more than homeostasis. Cell Cycle (2010) 0.79
Down-regulation of brain nuclear factor-kappa B pathway in the cyclooxygenase-2 knockout mouse. Brain Res Mol Brain Res (2005) 0.78
Neuronal overexpression of cyclooxygenase-2 does not alter the neuroinflammatory response during brain innate immune activation. Neurosci Lett (2010) 0.77
Lithium chloride, administered chronically to rats, does not affect the fractional phosphorylation of brain cytosolic phospholipase A2, while reducing its net protein level. Brain Res Bull (2003) 0.76
Altered mRNA editing and expression of ionotropic glutamate receptors after kainic acid exposure in cyclooxygenase-2 deficient mice. PLoS One (2011) 0.76
Decrease in the AP-2 DNA-Binding Activity and in the Protein Expression of AP-2 a and AP-2 b in Frontal Cortex of Rats Treated with Lithium for 6 Weeks. Neuropsychopharmacology (2018) 0.75